Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis

References

• World Health OrganizationGlobal Alliance Against Chronic Respiratory Diseases2008 Available from: http://www.who.int/gard/publications/Istanbul_report_final.pdfAccessed April 28, 2014
   Google Scholar
• KochanekKDXuJMurphySLMiniñoAMKungHCDeaths: Preliminary Data for 2009US Department of Health and Human Services, CDC, National Center for Health StatisticsNational Vital Statistics Reports2011 Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_04.pdfAccessed February 14, 2014
   Google Scholar
• HalbertRJNatoliJLGanoABadamgaravEBuistASManninoDMGlobal burden of COPD: systematic review and meta-analysisEur Respir J200628352353216611654
   PubMed Web of Science ®Google Scholar
• VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBTORCH InvestigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• GoldenbergMMPharmaceutical approval updateP T201338738940324049424
   PubMedGoogle Scholar
• LuGAdesAECombination of direct and indirect evidence in mixed treatment comparisonsStat Med200423203105312415449338
   PubMed Web of Science ®Google Scholar
• JansenJPCrawfordBBergmanGStamWBayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisonsValue Health200811595696418489499
   PubMed Web of Science ®Google Scholar
• ToftNInnocentGTGettinbyGReidSWAssessing the convergence of Markov Chain Monte Carlo methods: an example from evaluation of diagnostic tests in absence of a gold standardPrev Vet Med2007792–424425617292499
   PubMed Web of Science ®Google Scholar
• GuevaraJPBerlinJAWolfFMMeta-analytic methods for pooling rates when follow-up duration varies: a case studyBMC Med Res Methodol200441715248899
   PubMedGoogle Scholar
• SpiegelhalterDJBestNGCarlinBPVan Der LindeABayesian measures of model complexity and fitJ Royal Stat Soc: Series B2002644583639
   Google Scholar
• GlaxoSmithKlineA Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 μg Two Puffs bd and Fluticasone Propionate 250 μg Two Puffs bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks2005 Available from: http://www.gsk-clinicalstudyregister.com/files2/23674.pdfAccessed February 17, 2014
   Google Scholar
• AstraZenecaA phase III, 12-week, double-blind, randomised, parallel-group, active controlled, multinational, efficacy and safety study of Symbicort^® Turbuhaler^® 160/45 μg 2 inhalations twice daily (bid) compared to Oxis^® Turbuhaler^® 45 μg 2 inhalations twice daily (bid) in patients with chronic obstructive pulmonary disease [webpage on the Internet]Washington, DCNational Institutes of Health2010 [updated Sep 2012]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT1069289Accessed February 17, 2014
   Google Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsLancet Respir Med20131321022324429127
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200216681084109112379552
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJTrial of Inhaled STeroids ANd long-acting beta2 agonists study groupCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
   PubMed Web of Science ®Google Scholar
• HananiaNADarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPDChest2003124383484312970006
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112
   PubMed Web of Science ®Google Scholar
• KardosPWenckerMGlaabTVogelmeierCImpact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007175214414917053207
   PubMed Web of Science ®Google Scholar
• ZhengJPYangLWuYMThe efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPDChest200713261756176317951625
   PubMed Web of Science ®Google Scholar
• FergusonGTAnzuetoAFeiREmmettAKnobilKKalbergCEffect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsRespir Med200810281099110818614347
   PubMed Web of Science ®Google Scholar
• TashkinDPRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200018778120
   PubMed Web of Science ®Google Scholar
• AnzuetoAFergusonGTFeldmanGEffect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomesCOPD20096532032919863361
   PubMedGoogle Scholar
• RennardSITashkinDPMcElhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
   PubMed Web of Science ®Google Scholar
• CalverleyPMKunaPMonsóEBeclomethasone/formoterol in the management of COPD: a randomised controlled trialRespir Med2010104121858186820965712
   PubMed Web of Science ®Google Scholar
• SharafkhanehASouthardJGGoldmanMUryniakTMartinUJEffect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized studyRespir Med2012106225726822033040
   PubMed Web of Science ®Google Scholar
• TashkinDPDohertyDEKerwinEEfficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trialsInt J Chron Obstruct Pulmon Dis20127738622334770
   PubMed Web of Science ®Google Scholar
• ZhongNZhengJWenFEfficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary diseaseCurr Med Res Opin201228225726522046961
   PubMed Web of Science ®Google Scholar
• MartinezFJBosciaJFeldmanGFluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trialRespir Med2013107455055923332861
   PubMed Web of Science ®Google Scholar
• KerwinEMScott-WilsonCSanfordLA randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPDRespir Med2013107456056923352226
   PubMed Web of Science ®Google Scholar
• NanniniLJPoolePMilanSJHolmesRNormansellRCombined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201311CD00379424214176
   PubMed Web of Science ®Google Scholar